- Home
- PLX vs NYXH Comparison
PLX vs NYXH Comparison
Compare PLX & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PLX | NYXH |
|---|---|---|
| Founded | 1993 | 2009 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 182.9M | 161.9M |
| IPO Year | 1996 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PLX | NYXH |
|---|---|---|
| Price | $2.35 | $1.57 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $12.00 | $9.33 |
| AVG Volume (30 Days) | ★ 686.8K | 120.9K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $52,744,000.00 | N/A |
| Revenue This Year | $36.81 | $213.98 |
| Revenue Next Year | N/A | $126.25 |
| P/E Ratio | $8.74 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.47 | $1.26 |
| 52 Week High | $3.19 | $6.87 |
Technical Indicators
Market Signals| Indicator | PLX | NYXH |
|---|---|---|
| Relative Strength Index (RSI) | 48.40 | 51.25 |
| Support Level | $2.19 | $1.28 |
| Resistance Level | $2.43 | $1.70 |
| Average True Range (ATR) | 0.13 | 0.06 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 28.71 | 84.38 |
Price Performance
Historical ComparisonAbout PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.
About NYXH Nyxoah SA
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.